Suchergebnisse - "Chen, Jianhua"

PubPharm (18)

1

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study

enthalten in: Cancer communications (London, England) | 2024

von Zheng, J. | Wang, T. | Yang, Y. | +41

2

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

enthalten in: The New England journal of medicine | 2023

von Zhou, C. | Tang, K. | Cho, B. | +126

CommentIn: Cancer Discov. 2023 Dec 12;13(12):OF9. - PMID 37878779

3

Interim survival analysis of the randomized phase III GEMSTONE-302 trial : sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

enthalten in: Nature cancer | 2023

von Zhou, C. | Wang, Z. | Sun, M. | +31

ErratumIn: Nat Cancer. 2024 Jan 5;:. - PMID 38182915

4

Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients : a single-arm, multicenter phase II study (INTELLECT)

enthalten in: BMC medicine | 2023

von Shi, Y. | Chen, J. | Zhang, H. | +30

5

Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC : A Multicenter, Single-Arm, Open-Label, Phase 2 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Xiong, A. | Ren, S. | Liu, H. | +34

6

AENEAS : A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Lu, S. | Dong, X. | Jian, H. | +56

CommentIn: J Clin Oncol. 2022 Sep 20;40(27):3103-3105. - PMID 35679530

7

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC : Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Lu, S. | Wang, Q. | Zhang, G. | +39

CommentIn: Nat Rev Clin Oncol. 2022 Jan;19(1):6. - PMID 34845385

8

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer : a phase 1 dose-escalation and dose-expansion trial

enthalten in: Signal transduction and targeted therapy | 2022

von Shi, Y. | Fang, J. | Hao, X. | +26

9

Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC : A Single-Arm, Multicenter Phase 2 Study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2021

von Ai, X. | Wang, Q. | Cheng, Y. | +21

10

Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2021

von Yang, Y. | Huang, J. | Wang, T. | +41